Last updated: February 13, 2026
What Is the Current Market Status of NDC 00093-0752?
NDC 00093-0752 corresponds to a specific drug product approved by the FDA. The drug is identified as EpiPen (epinephrine auto-injector), 0.3 mg. It is indicated for immediate treatment of anaphylaxis caused by allergic reactions. As of 2023, EpiPen remains a dominant player in the emergency allergy management market.
Market dynamics are influenced by patent status, competition, and regulatory decisions. EpiPen historically held near 90% market share within the autoinjector allergen response segment, though generic competition has increased.
How Does the Competition and Patent Status Affect Pricing?
Patent and exclusivity status:
- Original patents for EpiPen expired in 2015, leading to biosimilar and generic entries such as Adrenaclick and generic epinephrine injectors.
- Despite patent expiration, Mylan (now part of Viatris), the original manufacturer, has employed strategies like authorized generics and formulation patents to maintain market share.
Market competition:
- Generics and authorized generics account for approximately 35-40% of prescriptions in 2022, reducing average prices.
- Patented formulations or delivery devices can command higher prices due to provider and consumer loyalty.
Pricing trend:
- The average retail price per EpiPen 2-pack was around $690 in 2016.
- While prices dropped post-generic entry, wholesale and list prices remains high, often exceeding $600 per 2-pack.
- Insurance coverage and manufacturer assistance programs heavily influence actual consumer costs.
What Are the Current Price Projections?
Short-term outlook (1-2 years):
- Wholesale prices: Continue to decline marginally due to increased competition and drug rebates.
- List prices: Remain around $600-$700 per 2-pack, with some market stabilization expected due to branding and patent strategies.
- Consumer costs: Largely depend on insurance networks, with copays typically between $0-$70 per pack.
Medium-term outlook (3-5 years):
- Generic penetration: Expected to increase, further reducing list prices.
- Manufacturers' strategies: Use of new formulations, such as needleless or more stable auto-injectors, can command premiums but face regulatory and development hurdles.
- Pricing trend: Wholesale prices projected to decline gradually, reaching approximately $400-$500 per 2-pack by 2025, contingent on market uptake of generics and biosimilars.
Long-term projections (5+ years):
- Market shifts: Possible introduction of new delivery mechanisms or reformulations that either price higher or lower depending on clinical advantages.
- Price stabilization: Likely around $300-$400 per 2-pack if biosimilar competition and regulatory policies favor price reductions.
Impact of Regulatory and Policy Changes
- FDA policies: Reimbursement and approval pathways for generics and biosimilars could accelerate price decline.
- Legislation: State laws mandating price transparency and limiting out-of-pocket costs may pressure manufacturers to lower prices.
- Medicaid and Medicare: Negotiation power increases with potential inclusion in drug formularies that favor lower-cost options.
Summary of Key Data Points
| Aspect |
Data Point |
Source |
| Original Brand Price (2016) |
~$690 per 2-pack |
[2] |
| Generic Market Share (2022) |
35-40% |
[3] |
| Typical Copay |
$0-$70 |
[4] |
| Projected Price (2025) |
$400-$500 per 2-pack |
Estimated |
| Patent Expiry |
2015 |
FDA records |
Key Takeaways
- The existing EpiPen product line faces price pressure from generics and biosimilars, with wholesale prices trending downward.
- Insurance coverage significantly influences actual consumer costs, often reducing out-of-pocket expenses.
- Regulatory environments and patent strategies will shape future pricing, with potential for further reductions or new premium formulations.
FAQs
1. How does generic competition influence EpiPen prices?
Generics and biosimilars typically reduce list prices through increased market share, but branded formulations can maintain premium pricing through branding and device differentiation.
2. Are new formulations of epinephrine auto-injectors in development?
Yes, several companies are exploring needleless and more stable formulations, potentially commanding higher prices if approved.
3. What factors could delay price reduction?
Patent litigation, patent extensions, or delays in biosimilar approvals can prolong premium pricing.
4. How do insurance policies affect patient costs?
Insurance plans often negotiate rebates and set copay levels, reducing the direct cost to consumers regardless of retail list prices.
5. What impact will legislation have on future pricing?
Legislation that mandates transparent pricing or allows government negotiation could further lower drug prices in this market.
Sources
- FDA Drug Database
- GoodRx Price History Data
- IQVIA National Prescription Audit
- Industry Reports on Auto-injector Market
